Rafferty Asset Management
IRWD icon

Rafferty Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Rafferty Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$760K Buy
216,623
+151,782
+234% +$622K ﹤0.01% 827
2025
Q4 		$219K Buy
+64,841
New +$168K ﹤0.01% 1081
2025
Q1 		– Sell
-236,732
Closed -$1.05M – 1110
2024
Q4 		$1.05M Sell
236,732
-159,932
-40% -$649K ﹤0.01% 783
2024
Q3 		$1.63M Buy
396,664
+12,312
+3% +$66.2K 0.01% 686
2024
Q2 		$2.51M Sell
384,352
-633,467
-62% -$4.48M 0.01% 583
2024
Q1 		$8.87M Buy
1,017,819
+316,049
+45% +$3.84M 0.03% 312
2023
Q4 		$8.03M Sell
701,770
-172,282
-20% -$1.7M 0.03% 336
2023
Q3 		$8.42M Buy
874,052
+148,881
+21% +$1.46M 0.05% 269
2023
Q2 		$7.72M Buy
725,171
+102,996
+17% +$1.11M 0.04% 298
2023
Q1 		$6.55M Sell
622,175
-58,837
-9% -$659K 0.04% 313
2022
Q4 		$8.44M Buy
681,012
+51,038
+8% +$579K 0.07% 238
2022
Q3 		$6.53M Buy
629,974
+304,990
+94% +$3.46M 0.07% 247
2022
Q2 		$3.75M Sell
324,984
-133,208
-29% -$1.57M 0.03% 344
2022
Q1 		$5.76M Sell
458,192
-18,594
-4% -$213K 0.03% 348
2021
Q4 		$5.56M Buy
476,786
+221,371
+87% +$2.72M 0.03% 348
2021
Q3 		$3.34M Buy
255,415
+33,038
+15% +$427K 0.02% 419
2021
Q2 		$2.86M Sell
222,377
-72,073
-24% -$825K 0.02% 518
2021
Q1 		$3.29M Buy
294,450
+228,223
+345% +$2.41M 0.02% 427
2020
Q4 		$754K Sell
66,227
-128,435
-66% -$1.41M 0.01% 588
2020
Q3 		$1.75M Buy
194,662
+106,277
+120% +$1.06M 0.02% 455
2020
Q2 		$912K Buy
88,385
+72,324
+450% +$740K 0.01% 572
2020
Q1 		$162K Sell
16,061
-147,926
-90% -$1.74M 0.01% 540
2019
Q4 		$2.18M Sell
163,987
-102,699
-39% -$1.13M 0.03% 357
2019
Q3 		$2.29M Buy
266,686
+9,440
+4% +$91.7K 0.04% 315
2019
Q2 		$2.81M Buy
257,246
+12,568
+5% +$141K 0.05% 269
2019
Q1 		$2.77M Buy
+244,678
New +$2.73M 0.04% 248

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rafferty Asset Management's IRWD Position: Q1 2026 in Review

Rafferty Asset Management increased its Ironwood Pharmaceuticals (IRWD) stake by 234% in Q1 2026, buying an estimated $622K and bringing the position to 216,623 shares worth $760K. The position accounts for ﹤0.01% of the portfolio, ranked #827.

Rafferty Asset Management first reported a position in IRWD in Q1 2019 and has held it in 26 quarters since. The position peaked at $8.87M in Q1 2024. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Rafferty Asset Management held 216,623 shares of Ironwood Pharmaceuticals worth $760K as of Q1 2026.
  • Rafferty Asset Management bought 151,782 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $622K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #827 holding.
  • Rafferty Asset Management first reported a position in Ironwood Pharmaceuticals in Q1 2019 and has held it in 26 quarters since.
  • Rafferty Asset Management's Ironwood Pharmaceuticals position peaked at $8.87M in Q1 2024.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.